Ost-müük Unicycive Therapeutics, Inc. - UNCY CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.06 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 1.41 |
Avatud* | 1.38 |
Aastane muutus* | 60.47% |
Päeva ulatus* | 1.31 - 1.39 |
52 nädala ulatus | 0.40-2.87 |
Keskmine maht (10 päeva) | 139.61K |
Keskmine maht (3 kuud) | 121.72M |
Turukapitalisatsioon | 20.57M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 15.23M |
Tulu | 1.63M |
EPS | -1.93 |
Dividendid (% kasumist) | N/A |
Beeta | -100.00K |
Järgmine tuluaruande kuupäev | N/A |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
May 26, 2023 | 1.33 | -0.03 | -2.21% | 1.36 | 1.39 | 1.31 |
May 25, 2023 | 1.41 | 0.05 | 3.68% | 1.36 | 1.41 | 1.36 |
May 24, 2023 | 1.40 | 0.05 | 3.70% | 1.35 | 1.41 | 1.35 |
May 23, 2023 | 1.35 | 0.01 | 0.75% | 1.34 | 1.40 | 1.31 |
May 22, 2023 | 1.34 | -0.01 | -0.74% | 1.35 | 1.39 | 1.31 |
May 19, 2023 | 1.33 | -0.04 | -2.92% | 1.37 | 1.37 | 1.31 |
May 18, 2023 | 1.37 | 0.03 | 2.24% | 1.34 | 1.41 | 1.34 |
May 17, 2023 | 1.36 | 0.07 | 5.43% | 1.29 | 1.37 | 1.22 |
May 16, 2023 | 1.31 | -0.09 | -6.43% | 1.40 | 1.40 | 1.30 |
May 15, 2023 | 1.37 | -0.05 | -3.52% | 1.42 | 1.42 | 1.34 |
May 12, 2023 | 1.34 | -0.07 | -4.96% | 1.41 | 1.47 | 1.33 |
May 11, 2023 | 1.45 | -0.03 | -2.03% | 1.48 | 1.51 | 1.37 |
May 10, 2023 | 1.47 | 0.00 | 0.00% | 1.47 | 1.54 | 1.41 |
May 9, 2023 | 1.50 | 0.07 | 4.90% | 1.43 | 1.52 | 1.36 |
May 8, 2023 | 1.43 | 0.10 | 7.52% | 1.33 | 1.46 | 1.30 |
May 5, 2023 | 1.32 | 0.07 | 5.60% | 1.25 | 1.39 | 1.24 |
May 4, 2023 | 1.29 | 0.13 | 11.21% | 1.16 | 1.34 | 1.16 |
May 3, 2023 | 1.22 | -0.01 | -0.81% | 1.23 | 1.28 | 1.21 |
May 2, 2023 | 1.24 | -0.07 | -5.34% | 1.31 | 1.31 | 1.21 |
May 1, 2023 | 1.25 | 0.02 | 1.63% | 1.23 | 1.30 | 1.23 |
Unicycive Therapeutics, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 0.951 | 0 | 0 | 0 | 0 |
Kogu tegevuskulu | 19.003 | 8.958 | 2.02 | 1.963 | 0.952 |
Müük/Üldine/admin kulud, kokku | 6.567 | 2.897 | 1.005 | 1.168 | 0.608 |
Uuringud ja arendus | 12.436 | 6.08 | 1.015 | 0.795 | 0.344 |
Tulud majandustegevusest | -18.052 | -8.958 | -2.02 | -1.963 | -0.952 |
Intressitulud (kulu), muud tulud, neto | -0.006 | -0.628 | -0.244 | -0.139 | -0.168 |
Muud, neto | 0 | -0.431 | 0 | -0.063 | 0 |
Netotulu enne makse | -18.058 | -10.017 | -2.264 | -2.165 | -1.12 |
Netotulu pärast makse | -18.058 | -10.017 | -2.264 | -2.165 | -1.12 |
Netotulu enne erikulusid | -18.058 | -10.017 | -2.264 | -2.165 | -1.12 |
Netotulu | -18.058 | -10.017 | -2.264 | -2.165 | -1.12 |
Arvestatav tulu, v a erikulud | -18.058 | -10.017 | -2.264 | -2.165 | -1.12 |
Arvestatav tulu, koos erikuludega | -18.058 | -10.017 | -2.264 | -2.165 | -1.12 |
Jaotamisele kuuluv netotulu | -18.058 | -10.017 | -2.264 | -2.165 | -1.12 |
Keskmine jaotamisele kuuluv aktsia kohta | 15.057 | 14.9965 | 14.4969 | 14.4969 | 14.4969 |
Jaotatav EPS, v a erakorralised kulud | -1.19931 | -0.66795 | -0.15617 | -0.14934 | -0.07726 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Jaotamisele kuuluv normaal-EPS | -1.19931 | -0.66922 | -0.15617 | -0.14934 | -0.07726 |
Ootamatud kulutused (tulu) | 0 | -0.019 | 0 | 0 | |
Tulu | 0.951 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kogutulu | 0.675 | 0 | 0.951 | 0 | 0 |
Kogu tegevuskulu | 4.877 | 5.325 | 6.505 | 3.636 | 3.537 |
Müük/Üldine/admin kulud, kokku | 1.847 | 1.485 | 1.702 | 1.776 | 1.604 |
Uuringud ja arendus | 3.03 | 3.84 | 4.803 | 1.86 | 1.933 |
Ootamatud kulutused (tulu) | 0 | 0 | 0 | 0 | |
Tulud majandustegevusest | -4.202 | -5.325 | -5.554 | -3.636 | -3.537 |
Intressitulud (kulu), muud tulud, neto | 0.002 | -0.003 | -0.003 | 0 | 0 |
Muud, neto | -10.375 | 0 | 0 | ||
Netotulu enne makse | -14.575 | -5.328 | -5.557 | -3.636 | -3.537 |
Netotulu pärast makse | -14.575 | -5.328 | -5.557 | -3.636 | -3.537 |
Netotulu enne erikulusid | -14.575 | -5.328 | -5.557 | -3.636 | -3.537 |
Netotulu | -14.575 | -5.328 | -5.557 | -3.636 | -3.537 |
Arvestatav tulu, v a erikulud | -14.767 | -5.328 | -5.557 | -3.636 | -3.537 |
Arvestatav tulu, koos erikuludega | -14.767 | -5.328 | -5.557 | -3.636 | -3.537 |
Jaotamisele kuuluv netotulu | -14.767 | -5.328 | -5.557 | -3.636 | -3.537 |
Keskmine jaotamisele kuuluv aktsia kohta | 15.2324 | 15.077 | 15.062 | 15.0287 | 15.0046 |
Jaotatav EPS, v a erakorralised kulud | -0.96945 | -0.35339 | -0.36894 | -0.24194 | -0.23573 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.96945 | -0.35339 | -0.36894 | -0.24194 | -0.23573 |
Tulu | 0.675 | 0 | 0.951 | ||
Total Adjustments to Net Income | -0.192 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Käibevarad kokku | 2.644 | 18.411 | 0.204 | 0.019 | 0.029 |
Raha ja lühiajalised investeeringud | 0.455 | 16.579 | 0 | 0.015 | 0.025 |
Cash | 0.455 | 16.579 | 0 | 0.015 | 0.025 |
Prepaid Expenses | 2.189 | 1.832 | 0.004 | 0.004 | 0.004 |
Other Current Assets, Total | 0.2 | 0 | 0 | ||
Total Assets | 2.818 | 18.744 | 0.204 | 0.019 | 0.029 |
Total Current Liabilities | 3.284 | 2.105 | 2.875 | 0.903 | 1.235 |
Accounts Payable | 0.892 | 0.742 | 0.184 | 0.322 | 0.06 |
Accrued Expenses | 2.392 | 1.363 | 0.168 | 0.013 | 0.017 |
Notes Payable/Short Term Debt | 0 | 0 | 0.986 | 0.46 | 0.147 |
Current Port. of LT Debt/Capital Leases | 0 | 1.528 | 0 | 0.9 | |
Other Current Liabilities, Total | 0 | 0.009 | 0.108 | 0.111 | |
Total Liabilities | 3.284 | 2.26 | 2.875 | 0.903 | 1.235 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | -0.466 | 16.484 | -2.671 | -0.884 | -1.206 |
Common Stock | 0.015 | 0.015 | 0.037 | 0.036 | 0.034 |
Additional Paid-In Capital | 33.516 | 32.408 | 3.214 | 2.738 | 0.253 |
Retained Earnings (Accumulated Deficit) | -33.997 | -15.939 | -5.922 | -3.658 | -1.493 |
Total Liabilities & Shareholders’ Equity | 2.818 | 18.744 | 0.204 | 0.019 | 0.029 |
Total Common Shares Outstanding | 15.2317 | 14.9965 | 14.4969 | 14.4969 | 14.4969 |
Property/Plant/Equipment, Total - Net | 0.174 | 0.333 | |||
Property/Plant/Equipment, Total - Gross | 0.181 | 0.334 | |||
Accumulated Depreciation, Total | -0.007 | -0.001 | |||
Other Liabilities, Total | 0 | 0.155 | |||
Preferred Stock - Non Redeemable, Net | 0 | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 26.184 | 2.644 | 9.962 | 12.56 | 15.464 |
Raha ja lühiajalised investeeringud | 24.332 | 0.455 | 7.01 | 10.573 | 13.62 |
Cash | 24.332 | 0.455 | 7.01 | 10.573 | 13.62 |
Prepaid Expenses | 1.852 | 2.189 | 2.952 | 1.987 | 1.844 |
Other Current Assets, Total | |||||
Total Assets | 27.202 | 2.818 | 10.177 | 12.816 | 15.76 |
Total Current Liabilities | 15.97 | 3.284 | 5.522 | 2.834 | 2.402 |
Accounts Payable | 0.79 | 0.892 | 2.292 | 0.747 | 0.589 |
Accrued Expenses | 1.974 | 2.392 | 3.23 | 2.087 | 1.813 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | |||||
Other Current Liabilities, Total | 13.206 | ||||
Total Liabilities | 16.685 | 3.284 | 5.551 | 2.906 | 2.516 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 10.517 | -0.466 | 4.626 | 9.91 | 13.244 |
Common Stock | 0.015 | 0.015 | 0.015 | 0.015 | 0.015 |
Additional Paid-In Capital | 33.475 | 33.516 | 33.28 | 33.007 | 32.705 |
Retained Earnings (Accumulated Deficit) | -48.572 | -33.997 | -28.669 | -23.112 | -19.476 |
Total Liabilities & Shareholders’ Equity | 27.202 | 2.818 | 10.177 | 12.816 | 15.76 |
Total Common Shares Outstanding | 15.2338 | 15.2317 | 15.0879 | 15.0445 | 15.0205 |
Property/Plant/Equipment, Total - Net | 1.018 | 0.174 | 0.215 | 0.256 | 0.296 |
Other Liabilities, Total | 0.715 | 0 | 0.029 | 0.072 | 0.114 |
Preferred Stock - Non Redeemable, Net | 25.599 | 0 | 0 | 0 | 0 |
Property/Plant/Equipment, Total - Gross | 1.026 | 0.181 | 0.221 | 0.26 | 0.299 |
Accumulated Depreciation, Total | -0.008 | -0.007 | -0.006 | -0.004 | -0.003 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -18.058 | -10.017 | -2.264 | -2.165 | -1.12 |
Raha majandustegevusest | -15.651 | -5.767 | -1.459 | -1.176 | -0.775 |
Mittelikviidsed varad | 1.222 | 4.354 | 0.971 | 0.684 | 0.339 |
Cash Taxes Paid | 0 | 0 | 0.001 | 0.002 | 0 |
Muutused tööjõus | 1.178 | -0.105 | -0.166 | 0.305 | 0.006 |
Rahavood investeeringutelt | -0.471 | 22.375 | 1.444 | 1.166 | 0.8 |
Rahavoogudesse investeerimine | -0.482 | 0 | -0.117 | 0 | 0 |
Aktsiate emiteerimine (tagasiost), neto | 0.011 | 22.39 | 0.141 | 1.166 | 0.25 |
Laenu väljastamine (kustutamine), neto | 0 | -0.015 | 1.42 | 0 | 0.55 |
Rahaline kogumuutus | -16.124 | 16.579 | -0.015 | -0.01 | 0.025 |
Raha majandustegevusest | 0.007 | 0.001 | |||
Tulu investeeringutelt | -0.002 | -0.029 | |||
Kapitalikulutused | -0.002 | -0.029 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -14.575 | -18.058 | -12.73 | -7.173 | -3.537 |
Cash From Operating Activities | -3.92 | -15.651 | -9.567 | -6.004 | -2.957 |
Non-Cash Items | 10.562 | 1.222 | 0.964 | 0.659 | 0.327 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | |
Changes in Working Capital | 0.091 | 1.178 | 2.194 | 0.506 | 0.251 |
Cash From Financing Activities | 27.797 | -0.471 | 0 | 0 | 0 |
Financing Cash Flow Items | -0.24 | -0.482 | 0 | ||
Issuance (Retirement) of Stock, Net | 28.037 | 0.011 | 0 | 0 | 0 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
Net Change in Cash | 23.877 | -16.124 | -9.569 | -6.006 | -2.959 |
Cash From Operating Activities | 0.002 | 0.007 | 0.005 | 0.004 | 0.002 |
Cash From Investing Activities | 0 | -0.002 | -0.002 | -0.002 | -0.002 |
Capital Expenditures | 0 | -0.002 | -0.002 | -0.002 | -0.002 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Gupta (Shalabh K) | Individual Investor | 38.5251 | 5868849 | 33906 | 2023-04-27 | |
Armistice Capital LLC | Hedge Fund | 6.4068 | 976000 | 176000 | 2022-12-31 | HIGH |
Rosalind Advisors, Inc. | Hedge Fund | 6.364 | 969484 | 0 | 2023-04-27 | |
Balyasny Asset Management LP | Hedge Fund | 4.7089 | 717349 | 717349 | 2023-03-31 | HIGH |
Nantahala Capital Management, LLC | Hedge Fund | 4.2499 | 647416 | 0 | 2023-03-31 | LOW |
Altium Growth GP, LLC | Corporation | 1.1553 | 176000 | 176000 | 2021-12-31 | |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.7553 | 115057 | 92362 | 2023-03-31 | LOW |
Laumas (Sandeep) | Individual Investor | 0.6946 | 105815 | 0 | 2023-04-27 | |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6295 | 95898 | 69789 | 2023-03-31 | LOW |
Jermasek (Douglas) | Individual Investor | 0.4621 | 70400 | 0 | 2023-04-27 | LOW |
Ryan (John L) | Individual Investor | 0.3817 | 58140 | 0 | 2023-04-27 | |
Schiller (Brigitte) | Individual Investor | 0.274 | 41738 | 0 | 2023-04-27 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.23 | 35036 | 35036 | 2023-03-31 | LOW |
Frontier Wealth Management LLC | Investment Advisor | 0.1234 | 18800 | 0 | 2022-06-30 | HIGH |
CAPTRUST Financial Advisors | Investment Advisor | 0.1234 | 18800 | 18800 | 2023-03-31 | LOW |
Tandem Capital Management, Inc. | Investment Advisor | 0.1017 | 15500 | 0 | 2023-03-31 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.0958 | 14600 | 14600 | 2023-03-31 | HIGH |
Oxbow Advisors, LLC | Investment Advisor | 0.0779 | 11861 | 11861 | 2023-03-31 | LOW |
Squarepoint Capital LLP | Investment Advisor/Hedge Fund | 0.0752 | 11459 | 11459 | 2023-03-31 | HIGH |
Tower Research Capital LLC | Hedge Fund | 0.0224 | 3419 | -1577 | 2023-03-31 | HIGH |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group530K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$46M+
Igakuine investeerimise maht
$31M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Unicycive Therapeutics, Inc. Company profile
Ettevõttest Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. on biotehnoloogiaettevõte, mis tegeleb teatavate meditsiiniliste seisundite ravimeetodite väljatöötamisega. Ettevõte keskendub meditsiiniliste seisundite tuvastamisele nii neeruhaiguste raames kui ka väljaspool. Tema arendusprogrammid keskenduvad kahe ravimeetodi väljatöötamisele: Renazorb kroonilise neeruhaigusega patsientide hüperfosfateemia raviks ja UNI 494 ägeda neerukahjustuse (AKI) raviks. Renazorbi töötas algselt välja Spectrum Pharmaceuticals ja litsentseeris selle Spectrum Pharmaceuticalsilt. UNI 494 on algselt välja töötatud vastavalt Sphaera Pharmaceuticals'i poolt ja litsentseeritud sellelt ettevõttelt.
Industry: | Biotechnology & Medical Research (NEC) |
4300 El Camino Real, Suite 210
LOS ALTOS
CALIFORNIA 94022
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 530,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com